Health Catalyst price target lowered to $3.75 from $4.50 at Stifel

Stifel analyst David Grossman lowered the firm’s price target on Health Catalyst (HCAT) to $3.75 from $4.50 and keeps a Hold rating on the shares after a “modest” Q3 revenue and EBITDA beat along with 2025 guidance being maintained. The absence of near-term catalysts is reflected in the multiple, but actions repositioning the business for growth and margin expansion create a potential opportunity for “those with longer-term perspective,” the analyst tells investors.